La investigación de biomarcadores en cáncer de vejiga optimiza la selección de pacientes candidatos a inmunoterapia Published on 23/09/2022 Un estudio, donde participa MD Anderson Cancer Center Madrid, muestra que la selección más certera de los pacientes que responderán a la inmunoterapia podría reducir los niveles de toxicidad, al evitar la administración de fármacos con reducidas probabilidades de éxito
The combination of targeted therapies and immunotherapy are the future for patients with advanced thyroid cancer Published on 19/09/2022 The new approach for the advanced stages of the disease incorporates immunotherapy to treatment, with the aim of maintaining the benefits of targeted therapies for the patient over time
A combination of chemotherapy and immunotherapy for the first time shows superiority over chemotherapy alone in metastatic bladder cancer Published on 08/10/2019 Dr. Enrique Grande, head of the Medical Oncology Service at MD Anderson Madrid, is co-chair of the IMvigor130 clinical trial, which has evaluated the efficacy of this combination in front line treatment
One in three patients on immunotherapy treatment has adverse effects involving the digestive system Published on 16/09/2019 MD Anderson Cancer Center Madrid experts advise the inclusion of specific recommendations at the nutritional level in these patients to avoid malnutrition, according to the conclusions of their research in more than 300 subjects